# Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients

Study · id `cardio:ct-nct03349684` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03349684](<https://clinicaltrials.gov/study/NCT03349684>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03349684

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 287 participants.

## Technical summary

Registry record NCT03349684. Randomized; quadruple masking; primary purpose treatment. Start 2018-03-05 (actual); primary completion 2019-08-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 287 participants (enrolled count; ClinicalTrials.gov record NCT03349684, source copy `cardio:ctgov-nct03349684-2020-08-05`, retrieved 2026-10-26)
- Started: 2018-03-05 (actual) (ClinicalTrials.gov record NCT03349684, source copy `cardio:ctgov-nct03349684-2020-08-05`, retrieved 2026-10-26)
- Primary completion: 2019-08-12 (actual) (ClinicalTrials.gov record NCT03349684, source copy `cardio:ctgov-nct03349684-2020-08-05`, retrieved 2026-10-26)
- Completion: 2019-08-21 (actual) (ClinicalTrials.gov record NCT03349684, source copy `cardio:ctgov-nct03349684-2020-08-05`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03349684, source copy `cardio:ctgov-nct03349684-2020-08-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03349684-2020-08-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Acarbose
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: d1f5b6997eebb9f6767ca694775bc9ba97b522d05df2aea30236413bade445dd
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
